Relay Therapeutics

Today, we shared with the Relay Therapeutics team that we are streamlining our operations and implementing cost reductions that result in ~70 people leaving Relay. This decision extends our cash runway to drive forward our clinical initiatives, to which we remain committed as ever. We are incredibly proud of the substantial progress our team has made. In ~10 years, we have evolved from an idea about how visualizing protein motion could inform drug discovery, to nominating eight development candidates and bringing four molecules into the clinic, one of which is the first ever mutant-selective PI3Kα inhibitor that we are preparing to initiate a Phase 3 registrational study in breast cancer in just a few months. Behind that is a clinical and preclinical pipeline with enormous potential to transform the lives of patients and their loved ones. Drug discovery and development is one of the most arduous endeavors we take on as a society. Every employee at Relay Therapeutics has played a role in building the company we are today, and we are personally grateful to each individual who has committed their career to bringing us to this pivotal moment. To our LinkedIn networks - if you see Relay Therapeutics on a resume, please be assured you will be adding a talented, relentless, and fearless individual to your team. Please reach out to recruiting@relaytx.com if you are hiring.

“I’ve had to fight for my life for my entire life. My whole life has been a fight – a fight not just to survive but to thrive.” – Lindsey Johnson Edwards Last week, we were fortunate to welcome Lindsey Johnson Edwards to Relay Tx to share her journey of living with CLOVES Syndrome, a type of vascular malformation. Her words are a powerful reminder of the challenges many individuals living with vascular malformations and progressive #rarediseases still face. Thank you, Lindsey, for continuing to educate us and sharing your invaluable insight as we advance our PIK3CA-driven Vascular Malformations program into the clinic this quarter.

Rare diseases are more common than many realize, affecting every 1 in 17 people worldwide. This #RareDiseaseDay, we're reminded that the impact of rare diseases is greater than most can imagine. At Relay Tx, we are committed to advancing research for these unmet needs and improving care for the rare community. 🦓

Today, in our Q4 and full year 2024 financial results, we highlighted the full trial design of our Phase 3 ReDiscover-2 trial of RLY-2608 + fulvestrant in PI3Kα-mutated, CDK4/6 pre-treated, HR+/HER2- advanced #breastcancer, which will initiate in mid-2025. Find full details here. https://lnkd.in/esBzRcTj

Survey data in #metastaticbreastcancer patients show they are just as concerned about quality of life and side effects of medication as they are about their disease progression. Dr. Sarah Sammons MD, a medical oncologist specializing in the care of patients with breast cancer at Dana-Farber and a primary investigator for Relay Tx’s ReDiscover trial, joined the Susan G. Komen Real Pink podcast to discuss the potential of personalized medicine in metastatic breast cancer. 

Our Director of Biology, Fabien Llambi, will present our differentiated preclinical work in #vascularmalformations at #VAC2025 this week. As we advance our commitment to innovation, we’re preparing to initiate the Phase 1 clinical trial of RLY-2608 in PI3Kα-driven vascular malformations by the end of Q1. This marks a significant milestone in our journey to develop transformative therapies for patients. Congratulations to Fabien and our entire vascular malformations team on this achievement! 🎉

Eight was great, but nine is divine! Today, we celebrate nine years of innovation, dedication, and impact. A huge thank you to our incredible team of Relayers and the patients, families, and investigators who inspire our mission every day. Here’s to the past, the future, and the lives we strive to change - cheers to 9! 🎂

Relay Therapeutics CEO Sanjiv Patel will present at #JPM25 on what's to come this year as we continue to transform the #drugdiscovery landscape. Find more details below. We look forward to connecting in San Francisco!

𝘛𝘪𝘥𝘪𝘯𝘨𝘴 𝘰𝘧 𝘤𝘰𝘮𝘧𝘰𝘳𝘵 𝘢𝘯𝘥 𝘫𝘰𝘺 🎁 This holiday season, Relayers partnered with Happy Hope Factory to assemble activity-filled bundles for children at our local Boston-area hospitals. Each bundle included games related to STEM and the arts, and hopefully lots of 𝘤𝘰𝘮𝘧𝘰𝘳𝘵 𝘢𝘯𝘥 𝘫𝘰𝘺, 𝘤𝘰𝘮𝘧𝘰𝘳𝘵 𝘢𝘯𝘥 𝘫𝘰𝘺.

Today, we announced updated data for RLY-2608 + fulvestrant that continue to demonstrate clinically meaningful progression free survival, which will be shared at #SABCS24 today. President of R&D Dr. Donald Bergstrom shares more about the significance of these data below. Tune into our conference call this morning, December 11, at 7:00AM ET for more insight. Learn more here. https://lnkd.in/erSDuRDJ